Journal of Endocrinological Investigation

, Volume 31, Issue 2, pp 163–168 | Cite as

Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in post-menopausal women

  • H. Uemura
  • T. Yasui
  • Y. Miyatani
  • M. Yamada
  • M. Hiyoshi
  • K. Arisawa
  • M. Irahara
Original Articles


Objective: The aim of this study was to elucidate the detail profiles of circulating osteoprotegerin (OPG) and soluble receptor activator of nuclear factor κB ligand (sRANKL) in post-menopausal women. Methods: Eighty Japanese post-menopausal women were enrolled in this cross-sectional study. Circulating OPG and free fraction of sRANKL (free sRANKL), PTH, calcium and phosphorus, age, years since menopause, body mass index, bone mineral density of the vertebral bodies (LBMD) and bone turnover markers were determined in each subject. Results: In rank order correlation analysis, serum OPG concentrations had a significant positive correlation with age (r=0.291, p=0.024) and a marginal significant negative correlation with LBMD (r=-0.247, p=0.062). However they did not have correlations with LBMD or other parameters after adjustment for age. Serum free sRANKL concentrations had a significant positive correlation with age (r=0.332, p=0.010) and a significant negative correlation with LBMD (r=−0.608, p<0.001). This correlation with LBMD persisted after adjustment for age. In a multiple regression analysis with a stepwise model, the main determinants of LBMD were age and serum free sRANKL (p=0.015 and p=0.006, respectively). Conclusions: We found the increase in circulating OPG and sRANKL with age and a robust negative correlation between circulating free sRANKL and LBMD after adjustment for age. The increase in circulating free sRANKL may reflect directly or indirectly the conditions coexistent with bone loss in post-menopausal women.

Key Words

Bone density bone metabolism post-menopausal women 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89: 309–19.PubMedCrossRefGoogle Scholar
  2. 2.
    Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93: 165–76.PubMedCrossRefGoogle Scholar
  3. 3.
    Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999, 96: 3540–5.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Ann Rev Immunol 2002, 20: 795–823.CrossRefGoogle Scholar
  5. 5.
    Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascularfunction. ArteriosclerThromb Vasc Biol 2002, 22: 549–53.CrossRefGoogle Scholar
  6. 6.
    Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001, 142: 5050–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998, 12: 1260–8.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397: 315–23.PubMedCrossRefGoogle Scholar
  9. 9.
    Lufkin EG, Wahner HW, O’Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992, 117: 1–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Chapurlat RD, Gamero P, Sornay-Rendu E, Arlot ME, Claustrat B, Delmas PD. Longitudinal study of bone loss in pre- and perimenopausal women: evidence for bone loss in perimenopausal women. Osteoporos Int 2000, 11: 493–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999, 14: 518–27.PubMedCrossRefGoogle Scholar
  12. 12.
    Hofbauer LC, Schoppet M, Schüller P, Viereck V, Christ M. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol 2004, 60: 214–9.CrossRefGoogle Scholar
  13. 13.
    Schett G, Kiechl S, Redlich K, et al. Soluble RANKL and riskof nontraumatic fracture. JAMA 2004, 291: 1108–13.PubMedCrossRefGoogle Scholar
  14. 14.
    Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001, 86: 3162–5.PubMedGoogle Scholar
  15. 15.
    Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C, et al. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. Wien Klin Wochenschr 2003, 115: 291–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Ziolkowska M, Kurowska M, Radzikowska A. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor treatment. Arthritis Rheum 2002, 46: 1744–53.PubMedCrossRefGoogle Scholar
  17. 17.
    Kudlacek S, Schneider B, Woloszczuk W, et al. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003, 32: 681–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Liu JM, Zhao HY, Ning G, et al. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20–75. Calcif Tissue Int 2005, 76: 1–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002, 87: 4470–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Browner WS, Lui LY, Cummings SR. Association of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001, 86: 631–7.PubMedGoogle Scholar
  21. 21.
    Indridason OS, Franzson L, Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 2005, 16: 417–23.PubMedCrossRefGoogle Scholar
  22. 22.
    Kazama JJ, Shigematsu T, Yano K, et al. Increased circulating levels of osteoclastogenesis-inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002, 39: 525–32.PubMedCrossRefGoogle Scholar
  23. 23.
    Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003, 88: 1024–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003, 111: 1221–30.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Trofimov S, Pantsulaia I, Kobyliansky E, Livshits G. Circulationg levels of receptor activator of nuclear factor-ÎB ligand/osteoportegerin/macrophage-colony stimulating factor in a presumably healthy human population. Eur J Endocrinol 2004, 150: 305–11.PubMedCrossRefGoogle Scholar
  26. 26.
    Pulsatelli L, Dolzani P, Silvestri T, et al. Soluble receptor activator of nuclear factor-κB ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases. Biogerontology 2004, 5: 119–27.PubMedCrossRefGoogle Scholar
  27. 27.
    Schett G, Kiechl S, Redlich K, et al. Soluble RANKL and risk of nontraumatic fracture. JAMA 2004, 291: 1108–13.PubMedCrossRefGoogle Scholar
  28. 28.
    Abrahamsen B, Hjelmborg JV, Kostenuik P, et al. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Bone 2005, 36: 727–35.PubMedCrossRefGoogle Scholar
  29. 29.
    Martini G, Gennari L, Merlotti D, et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget’s disease of bone. Bone 2007, 40: 457–63.PubMedCrossRefGoogle Scholar
  30. 30.
    Dovio A, Data V, Angeli A. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? J Endocrinol Invest 2005, 28 (Suppl 10): 14–22.PubMedGoogle Scholar
  31. 31.
    Alvarez L, Peris P, Guañabens N, et al. Serum osteoprotegerin and its ligand in Paget’s disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum 2003, 48: 824–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Nakashima T, Kobayashi Y, Yamasaki S, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000, 275: 768–75.PubMedCrossRefGoogle Scholar
  33. 33.
    Yeung RS. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss. J Rheumatol 2004, 31: 844–6.PubMedGoogle Scholar
  34. 34.
    Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005, 90: 6323–31.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2008

Authors and Affiliations

  • H. Uemura
    • 1
    • 2
  • T. Yasui
    • 2
  • Y. Miyatani
    • 2
  • M. Yamada
    • 2
  • M. Hiyoshi
    • 1
  • K. Arisawa
    • 1
  • M. Irahara
    • 2
  1. 1.Department of Preventive Medicine, Institute of Health BiosciencesThe University of Tokushima Graduate SchoolTokushimaJapan
  2. 2.Department of Obstetrics and Gynecology, Institute of Health BiosciencesThe University of Tokushima Graduate SchoolJapan

Personalised recommendations